Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life

[1] Tani C(2013)Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients Autoimmunity Reviews 12 537-541

[2] D’Aniello D(2014)Systemic lupus erythematosus Lancet 384 1878-1888

[3] Delle Sedie A(2010)Rheumatoid arthritis Lancet 376 1094-1108

[4] Carli L(2014)Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials Annals of the Rheumatic Diseases 73 838-844

[5] Cagnoni M(2014)The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial The Journal of Rheumatology 41 1067-1076

[6] Possemato N(1992)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Medical Care 30 473-483

[7] Lisnevskaia L(2008)Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis The Journal of Rheumatology 35 1528-1537

[8] Murphy G(1997)Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus The Journal of Rheumatology 24 1608-1614

[9] Isenberg D(2014)The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism 44 123-130

[10] Scott DL(2009)Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: A 2-year prospective study Scandinavian Journal of Rheumatology 38 121-127

[1] Tani C(2013)Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients Autoimmunity Reviews 12 537-541

[2] D’Aniello D(2014)Systemic lupus erythematosus Lancet 384 1878-1888

[3] Delle Sedie A(2010)Rheumatoid arthritis Lancet 376 1094-1108

[4] Carli L(2014)Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials Annals of the Rheumatic Diseases 73 838-844

[5] Cagnoni M(2014)The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial The Journal of Rheumatology 41 1067-1076

[6] Possemato N(1992)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Medical Care 30 473-483

[7] Lisnevskaia L(2008)Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis The Journal of Rheumatology 35 1528-1537

[8] Murphy G(1997)Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus The Journal of Rheumatology 24 1608-1614

[9] Isenberg D(2014)The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism 44 123-130

[10] Scott DL(2009)Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: A 2-year prospective study Scandinavian Journal of Rheumatology 38 121-127